首页> Leukemia research> Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tingting,Li

第一单位： National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215123, China.

作者： Tingting,Li ^[1] ; Qingya,Cui ^[1] ; Sining,Liu ^[1] ; Zheng,Li ^[1] ; Wei,Cui ^[1] ; Mengyun,Li ^[1] ; Yunju,Ma ^[1] ; Xuanqi,Cao ^[1] ; Xiaming,Zhu ^[1] ; Liqing,Kang ^[2] ; Lei,Yu ^[2] ; Depei,Wu ^[1] ; Xiaowen,Tang ^[3]

作者单位： National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215123, China. ^[1] East China Normal University, Shanghai 200062, China; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai 201203, China. ^[2] National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215123, China. Electronic address: xwtang1020@163.com. ^[3]

关键词 CAR-T therapy Decitabine maintenance strategy survival outcomes